StockMacro
Company, fund or insider

Help

Menu

Paul Bisaro

Insider (Form 4 reporting owner): Director CIK 1237253Name as filed: Bisaro PaulIts filings on EDGARAll insiders

Measures activity, not value. Not investment advice.

Since 12 Mar 2019, bought $479K in 5 open-market purchases across 4 companies.

Companies

Role on the latest Form 4 for each; open-market trades counted
CompanyRoleTrades fromtoPurchasesSales
Amneal Pharmaceuticals AMRXExecutive Chairman12 Mar 201912 Mar 20191$203K–
Zoetis ZTSDirector13 May 202613 May 20261$152K–
TherapeuticsMD TXMDDirector4 Jun 202016 Aug 20212$96K–
Myriad Genetics MYGNDirector14 May 202614 May 20261$28K–

What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.

Median return minus the sector fund, in percentage points; "too few trades" under 5
Open-market tradesAfter 3 monthsAfter 6 monthsAfter 12 months
After purchases-29.9 pts5 trades, 20% above the sector-25.0 pts5 trades, 20% above the sectortoo few trades3 trades

For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.

By year

Counted open-market trades, by trade date
YearPurchasesBoughtSalesSoldNet
20262$179K––$179K
20211$40K––$40K
20201$57K––$57K
20191$203K––$203K

Every trade

5, newest first; open-market purchases and sales only
Trade dateCompanySideSharesPriceValuePlanned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. Filing
14 May 2026Myriad Genetics MYGNBuy7,500$3.69$28KNoForm 4filed 14 May 2026
13 May 2026Zoetis ZTSBuy2,000$75.88$152KNoForm 4filed 13 May 2026
16 Aug 2021TherapeuticsMD TXMDBuy50,000$0.79$40KNot statedForm 4filed 18 Aug 2021
4 Jun 2020TherapeuticsMD TXMDBuy50,000$1.14$57KNot statedForm 4filed 8 Jun 2020
12 Mar 2019Amneal Pharmaceuticals AMRXBuy17,000$11.97$203KNot statedForm 4filed 12 Mar 2019

From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.